Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials
- [Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials – Author's reply
- [Comment] Precision medicine in type 2 diabetes: should clustering be used?
- [Editorial] Safeguarding paediatric metabolic health
- [Articles] Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
- [Comment] What Mauritius teaches us about diabetes surveillance
- [Articles] Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial
- [Comment] Petrelintide and the evolving role of amylin agonism in obesity
- [Personal View] Disease modification outcomes in type 2 diabetes: a modified Delphi
- [Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 149–56
- [Review] Hypoparathyroidism: translating science from the laboratory to the clinic
- [Articles] Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case–control study
- [Review] From adiposity to multisystem morbidity: the case for weight loss as disease modification
- [Editorial] Diabetes in a warming world
- [Articles] Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial
- [Comment] The glucagon renaissance in obesity therapeutics
- [Correspondence] Time for personalised incretin titration
- [Articles] Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial
- [Comment] Safety and tolerability of orforglipron in Japanese people with type 2 diabetes
- [In Focus] Toxic chemicals: the fight for planetary health